SNOANasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals develops and sells stabilized hypochlorous acid (HOCl) products used in wound care, eye care, oral care, dermatology, podiatry, animal health care, and surface disinfection. The company operates through a U.S. parent with subsidiaries in Mexico and the Netherlands and sells through direct channels and partners in more than 55 countries.

Kysy yhtiöstä
Liikevaihto19,5milj. USD
+36,7 %v/v
Liikevoitto (EBIT)−2,5milj. USD
+33,7 %v/v
EBIT-marginaali−12,6%
+13,4 %-yks.v/v
Nettotulos−3,2milj. USD
+8,2 %v/v
Vapaa kassavirta−4,1milj. USD
−2 355,4 %v/v

Tilikausi 2026 · muutos edellisvuodesta

Kehitys 2021–2026

−1001020milj. USD2021: 19 milj. USD2021: EBIT −3,4 milj. USD20212022: 13 milj. USD2022: EBIT −5,9 milj. USD20222023: 13 milj. USD2023: EBIT −4,6 milj. USD20232024: 13 milj. USD2024: EBIT −4,7 milj. USD20242025: 14 milj. USD2025: EBIT −3,7 milj. USD20252026: 20 milj. USD2026: EBIT −2,5 milj. USD202620−2,5
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Wound care30 %

HOCl-based solutions and gels used for wound cleansing, irrigation, and skin protection.

Eye care15 %

Prescription and OTC products for eyelid, periocular, and blepharitis-related care.

Dermatology25 %

Products for acne, scar management, atopic dermatitis, and skin irritation.

Disinfectants and sanitizers15 %

Hard-surface disinfectant and sanitizer products sold through partners and distributors.

Animal health and other applications15 %

HOCl products used in veterinary and other specialized care applications.

Asiakkaat

Sonoma sells to distributors, retail partners, healthcare channels, and other commercial customers that market or use HOCl-based products. Its end markets include human healthcare, consumer health, veterinary care, and surface disinfection, with demand coming from both domestic and international buyers. The company also relies on a small number of customers that can represent a meaningful share of revenue in a given period.

Distributors and channel partners

Buy HOCl products for resale across international and U.S. markets; important because Sonoma relies on partner-led commercialization.

Retail consumers via OTC channels

Buy acne, wound care, and skin-care products through retailers and consumer health channels.

Healthcare professionals and clinics

Use prescription and professional-grade eye, wound, and dermatology products for patient care.

Veterinary and animal health customers

Buy HOCl-based products for animal care and related hygiene applications.

Surface disinfection customers

Buy hard-surface disinfectants and sanitizers through partners such as MicroSafe.

Strategia

Sonoma's strategy centers on expanding distribution, securing regulatory clearances, and broadening the use of its HOCl platform across healthcare and consumer channels. It also seeks to deepen international reach, relaunch and extend product lines, and use partner-led commercialization to scale into new markets. The company continues to invest in product development and approvals to support market access and product breadth.

Expand partner-led distributionLyhyt aikaväli

The business depends on channel partners to reach retailers, healthcare buyers, and international markets.

Increase regulatory reachKeskipitkä aikaväli

Approvals and clearances determine where HOCl products can be marketed and how broadly they can be sold.

Broaden product portfolioKeskipitkä aikaväli

A wider product set supports cross-selling across wound care, dermatology, eye care, and consumer channels.

Grow international commercializationPitkä aikaväli

International markets are a major revenue source and diversify demand beyond the U.S.

Maantiede

Sonoma has material international operations, with most revenue generated outside the United States and sales in over 55 countries. In the latest quarterly disclosures, Europe was the largest region, followed by the United States, Asia, Latin America, and the Rest of the World. The company also manufactures through its Mexico subsidiary and serves Europe through its Netherlands subsidiary.

Riskit

Sonoma faces regulatory, quality, and commercialization risks because its HOCl products are sold in regulated healthcare and consumer categories across many countries. The company also depends on a small number of customers and third-party partners, which can create revenue volatility if demand shifts, approvals are delayed, or a partner underperforms. International exposure adds foreign exchange, tariff, and local compliance risk.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Regulatory non-compliance or delayed approvals1Dependence on third-party partners and contractors2Customer concentration3Product liability and recall risk4International operating risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Regulatory non-compliance or delayed approvalsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    HOCl products require FDA and international clearances, and changes in labeling or quality systems can delay commercialization.

    Kohdistuu: Product manufacturing and marketing

  2. Dependence on third-party partners and contractorsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on collaborators, suppliers, and distributors for manufacturing and market access.

    Kohdistuu: Supply chain and commercialization

  3. Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    A small number of customers can account for a significant portion of revenue in a given year.

    Kohdistuu: Revenue concentration

  4. Product liability and recall riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Healthcare and disinfectant products can face recalls, claims, or reputational damage if performance or labeling is challenged.

    Kohdistuu: Brand and sales channels

  5. International operating riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Most revenue is generated outside the U.S., increasing exposure to currency, tariffs, and local regulation.

    KohdistuuEuropeAsiaLatin AmericaOther foreign markets

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and channel timing

Sales through distributors, retailers, and international partners can create timing differences between shipment and end-demand.

Vaikutus: Quarterly comparability and reported revenue

Allowance for doubtful accounts

Customer concentration and international collections increase credit-risk judgment.

Vaikutus: Net receivables and operating expense

Inventory reserves and write-downs

Product shelf life, regulatory changes, and demand shifts can require reserve adjustments.

Vaikutus: Gross margin and inventory carrying value

Deferred tax asset valuation allowance

Loss history and uncertain future taxable income require management to assess realizability.

Vaikutus: Income tax expense and balance sheet assets

Equity financing and share-based transactions

The company has historically funded operations with equity issuances and related financing activities.

Vaikutus: Share count, capital structure, and financing cash flows

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Lexicon Pharmaceuticals, Inc

LXRX · Pharmaceutical Preparations

Alcon Inc

ALC · Ophthalmic Goods

Sonos Inc

SONO · Household Audio & Video Equipment

Ecolab Inc

ECL · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics

Cencora, Inc.

COR · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Anebulo Pharmaceuticals, Inc.

ANEB · Pharmaceutical Preparations

Päivitetty: 24.9.2026